Navigation Links
Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
Date:5/8/2012

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking. Intermezzo has gender-specific dosing (1.75 mg for adult women and 3.5 mg for adult men) taken only once per night as needed if a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo 1.75 mg is also the recommended dose for men and women over 65 years of age, patients with hepatic impairment, or patients taking concomitant CNS depressants.

In the double-blind, placebo-controlled, cross-over pharmacokinetic study in healthy volunteers, Intermezzo doses of 1.0 mg, 1.75 mg, and 3.5 mg were administered on two consecutive days to 11 women and 13 men. At the same dose, the plasma levels of zolpidem tartrate in women were approximately 45 percent higher than in men. The study found that women taking a 3.5 mg dose cleared the drug at a slower rate than men taking 3.5 mg (2.7 ml/min/kg vs. 4.00 ml/min/kg, respectively).

"Given that women clear the active ingredient in Intermezzo at a lower rate than men, the results of the study support a recommended lower dosage of Intermezzo for women and a higher dosage for men," said study co-author Thomas Roth, Ph.D., Director of Sleep Medicine at Henry Ford Hospital in Detroit.

Intermezzo was approved by the FDA in November 2011 and is available nationwide in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. Intermezzo contains a bicarbonate-carbonate buffer. On average, Intermezzo is rapidly absorbed in both genders, achieving peak mean plasma levels of zolpidem in
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
7. Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
8. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
9. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
10. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Calif., Jan. 28 Impact Medical Solutions, Inc. (OTC ... that Mr. Mark A. Billings has joined the Company,s ... Partner at Atwater Financial Group Inc., a Montreal-based financial ... small-cap companies. He is also the President and ...
... ticker symbol ,CDXP.OB, LA JOLLA, Calif., Jan. 28 ... that it has completed a corporate name change to ... change, the Over-the-Counter Bulletin Board will trade the Company,s ... Kuo, M.D., Cordex,s Chief Executive Officer commented, "We are ...
Cached Medicine Technology:Impact Medical Solutions Announces Appointment of New Director and Corporate Update 2Impact Medical Solutions Announces Appointment of New Director and Corporate Update 3Duska Therapeutics Completes Corporate Name Change to Cordex Pharma 2Duska Therapeutics Completes Corporate Name Change to Cordex Pharma 3
(Date:7/10/2014)... News) -- Adults with dyslexia are more likely to ... teenagers than people who don,t have the learning disorder, ... affects up to 10 percent of people, causes problems ... of adults with this condition said they suffered physical ... those without dyslexia. "Even after accounting for age, ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... may help ease the hot flashes that often accompany menopause, ... more than 50 percent of menopausal women, said Dr. Taraneh ... science at the Icahn School of Medicine at Mount Sinai ... experience more than 10 hot flashes a day, and she ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... the Twitter wars that break out regularly between outspoken celebrities ... for your own relationship, a new study suggests. High ... couple, even if the couple is in a long-term relationship, ... users. In turn, that friction can lead to cheating ...
(Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... OXFORD, England, July 13 International medical,communications ... the Year at the Communique Awards in London ... by an independent panel of,communications experts, who assess ... for healthcare clients, along with business strategy,client retention, ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a ... scheduled a conference call and web cast on Thursday, July 30, 2009, ... ended June 28, 2009. Gentiva plans to issue its financial news release ... , The conference call is open to investment analysts ...
... July 13 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment ... has received a $1.5 million milestone payment from Biogen ... of a Raf kinase inhibitor development candidate for the ...
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SUNNYVALE, Calif., July 13 Cepheid (Nasdaq: CPHD ... & Drug Administration (FDA) to market its Xpert(R) C. difficile ... of the bacterium that causes Clostridium difficile infection (CDI). ... for CDI to deliver both rapid turnaround and a high degree ...
... , PORT WASHINGTON, N.Y., July 13 ... of the American Medical Association has granted a CPT Category ... (TM) (MCG) system. MCG is the World,s first Internet based, ... for interactive online diagnosis. The MCG is intended as ...
Cached Medicine News:Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 2Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 3Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 4Health News:Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 2Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 3Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 4Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 5Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2
... provided by a cool-running, energy efficient LEDs ... you need to see without affecting the ... they are maintenance free so you'll never ... Phoroptor comes with a limited lifetime warranty, ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: